Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metastatic Urothelial Carcinoma

 Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metastatic Urothelial Carcinoma

Shots:

  • The P-1b/2 KEYNOTE-146/Study 111 trial involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg IV q3w) in patients with NSCLC, Advanced melanoma & urothelial cancer
  • P1b/2 KEYNOTE-146/Study 111 results: NSCLC: ORR 33.3%, mPFS 5.9 mos., mDOR 10.9 mos.; Advanced melanoma: ORR 47.6%, mPFS 5.5 mos., mDOR (12.5 mos.); Metastatic Urothelial Carcinoma: ORR 25%, mPFS 5.4 mos., Collectively was well tolerated
  • Lenvima PO is a mAb, kinase inhibitor of VEGF receptors, and is approved for refractory thyroid cancer in 50 countries. In Mar 2018, Merck & Eisai collaborated to co-develop Lenvima globally

Click here to read full press release/ article | Ref: Eisai | Image: The Business Journals

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post